Across TCGA pan-cancer cohorts, ID2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ID2 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ID2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ID2 expression acts as an unfavorable survival marker.
BLCA and LIHC are the cancer types where ID2 Mutation most reproducibly stratifies survival.